ASH 2022 Conference Coverage
Updated Results From the Momentum Phase 3 Study of Momelotinib vs. Danazol in Symptomatic and Anemic MF Pts Previously Treated With a JAK Inhibitor
By
ASH 2022 Conference Coverage
FEATURING
Aaron Gerds
By
ASH 2022 Conference Coverage
FEATURING
Aaron Gerds
Login to view comments.
Click here to Login
